Adaptive Biotechnologies ADPT Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Business | ||||||
| Immune Medicine Business | $3.78M-61.4% | $9.79M-73.7% | $37.19M+316% | $8.94M+2.5% | $8.72M+19.3% | |
| Mrd Business | $67.09M+8.4% | $61.89M+9.0% | $56.79M+13.7% | $49.94M+14.2% | $43.72M+8.9% | |
| Revenue by Product | ||||||
| Collaboration Revenue | $0— | $0-100% | $33.74M+756% | $3.94M+9.4% | $3.6M+3.0% | |
| Regulatory Milestone Revenue | $9M+200% | $3M-53.8% | $6.5M+18.2% | $5.5M+22.2% | $4.5M— | |
| Service And Licensing Revenue | $3.78M-35.3% | $5.84M0.0% | $5.84M0.0% | $5.84M0.0% | $5.84M+16.9% | |
| Service | $58.09M-1.3% | $58.89M+17.1% | $50.29M+13.2% | $44.44M+13.3% | $39.22M-2.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Adaptive Biotechnologies break its business down?
- Adaptive Biotechnologies (ADPT) reports revenue by business across 2 parts — Immune Medicine Business and Mrd Business. Each is extracted from the segment footnotes and tracked over time.
- Where does Adaptive Biotechnologies's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Adaptive Biotechnologies's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
